J Korean Med Assoc.  2015 Nov;58(11):989-994. 10.5124/jkma.2015.58.11.989.

Prenatal maternal serum screening for fetal aneuploidy

• Lee SW

• KMID: 2195127
• DOI: http://doi.org/10.5124/jkma.2015.58.11.989

Abstract

During recent decades, prenatal screening strategies have evolved greatly. Prenatal screening, including the diagnosis of fetal aneuploidy, includes invasive and non-invasive methods. Various combinations of first and second trimester maternal serum analytes and fetal ultrasound measurements have been proposed to construct a screening method with high sensitivity and specificity. Non-invasive tests are performed either by maternal serum analyte screening alone (double marker test, triple test, quadruple test, or serum integrated test), serum screening combined with ultrasound (integrated test, sequential test, or contingent test), or most recently, the cell-free fetal DNA test. Recent advances in prenatal screening methods have resulted in tremendous advantages to patients and healthcare providers. Therefore new approaches to counseling are necessary to ensure that all patients and healthcare providers receive the most comprehensive access to prenatal screening and diagnostic testing options. This article summarizes the various prenatal maternal serum screening options for fetal aneuploidy.

Keyword

Prenatal diagnosis; Aneuploidy

MeSH Terms

Aneuploidy*
Counseling
Diagnosis
Diagnostic Tests, Routine
DNA
Female
Health Personnel
Humans
Mass Screening*
Pregnancy
Pregnancy Trimester, Second
Prenatal Diagnosis
Sensitivity and Specificity
Ultrasonography
DNA

Reference

1. ACOG Committee on Practice Bulletins. ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol. 2007; 109:217–227.

2. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen. 2003; 10:56–104.

3. Malone FD, Wald NJ, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor IE, Carr SR, Wolfe HM, Dukes KA, Bianchi DW, Rudnicka A, Hackshaw A, Lambert-Messerlian G, D'Alton ME. First- and Second-trimester Evaluation of Risk (FASTER) trial: principal results of the NICHD Multicenter Down Syndrome Screening Study. Am J Obstet Gynecol. 2003; 189:S56.

4. Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol. 1984; 148:886–894.

5. Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn. 1987; 7:623–630.

6. Saller DN Jr, Canick JA, Oyer CE. The detection of non-immune hydrops through second-trimester maternal serum screening. Prenat Diagn. 1996; 16:431–435.

7. Jorgensen PI, Trolle D. Low urinary oestriol excretion during pregnancy in women giving birth to infants with Down's syndrome. Lancet. 1972; 2:782–784.

8. Canick JA, Knight GJ, Palomaki GE, Haddow JE, Cuckle HS, Wald NJ. Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome. Br J Obstet Gynaecol. 1988; 95:330–333.

9. Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, Haddow JE, Knight GJ, Palomaki GE, Canick JA. Maternal serum screening for Down's syndrome in early pregnancy. BMJ. 1988; 297:883–887.

10. Groome NP, Evans LW. Does measurement of inhibin have a clinical role? Ann Clin Biochem. 2000; 37(Pt 4):419–431.

11. Van Lith JM, Pratt JJ, Beekhuis JR, Mantingh A. Second-trimester maternal serum immunoreactive inhibin as a marker for fetal Down's syndrome. Prenat Diagn. 1992; 12:801–806.

12. Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CH, Hankins G, Berkowitz RL, Merkatz I, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Vidaver J, D'Alton ME. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol. 2004; 191:1446–1451.

13. Wapner RJ. First trimester screening: the BUN study. Semin Perinatol. 2005; 29:236–239.

14. Kim MH, Park SH, Cho HJ, Choi JS, Kim JO, Ahn HK, Shin JS, Han JY, Kim MY, Yang JH. Threshold of nuchal translucency for the detection of chromosomal aberration: comparison of different cut-offs. J Korean Med Sci. 2006; 21:11–14.

15. Cuckle H, Benn P, Wright D. Down syndrome screening in the first and/or second trimester: model predicted performance using meta-analysis parameters. Semin Perinatol. 2005; 29:252–257.

16. Choi YK, Kim MY, Han JY, Ryu HM, Yang JH, Kim ES, Lee HB, Han IS, Ko MI, Han HW. A study about the effectiveness of triple marker test as a screening test for chromosomal aneuploidy. Korean J Obstet Gynecol. 1999; 42:1935–1942.

17. American College of Obstetricians and Gynecologists Committee on Genetics. Committee Opinion No. 545: noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol. 2012; 120:1532–1534.